SynthesisRheumatology international2022
Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle income countries: a systematic review and meta-analysis.
Synthesis in Rheumatology international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Barriers and facilitators associated with diagnostic and treatment delays in lupus in the Global South and North: a systematic review of qualitative and mixed methods studies.Rheumatology international · 2025Pooled it
- Trends in systemic lupus erythematosus incidence and prevalence among Korean women of childbearing age: a nationwide study 2011~2020.Journal of rheumatic diseases · 2026Article
- Urinary Exosomes as Potential Biomarkers for Diagnosis, Disease Activity Assessment, Treatment Monitoring, and Prognosis in Lupus Nephritis.International journal of molecular sciences · 2026Review
- Divergence between initial and cumulative manifestations in systemic lupus erythematosus: effect of age and sex in a prospective lupus cohort from Pakistan.Annals of medicine and surgery (2012) · 2026Article
- Association of metabolic syndrome and its components with systemic lupus erythematosus.BMC endocrine disorders · 2026Article
- Targeting JAK/STAT signalling with cold atmospheric plasma: a potential therapy for systemic lupus erythematosus.Expert reviews in molecular medicine · 2026Review
- Tapering strategies for immunosuppressive, corticosteroid, and biologic therapy in lupus nephritis: a national survey of rheumatology and nephrology practices in Saudi Arabia.Rheumatology international · 2026Article
- A bibliometric analysis on immunotherapy treatments for systemic lupus erythematosus: analysis of published evidence from 2014 to 2024.Clinical rheumatology · 2026Article
- Regional variation in serum ficolin levels and their association with disease activity and clinical manifestations in systemic lupus erythematosus (SLE) patients from India.Immunologic research · 2026Article
- Examining the Effectiveness of Acceptance and Commitment Therapy on the Cognitive Functions of Patients with Systemic Lupus Erythematosus.Iranian journal of psychiatry · 2026Article
- Plasma catecholamine metabolites are associated with disease activity and pathophysiological features in systemic lupus erythematosus using targeted LC-MS/MS.Scientific reports · 2025Article
- Complete blood count-derived biomarkers as indicators of systemic lupus erythematosus activity: a cross-sectional comparative study.Lupus science & medicine · 2025Article
- Prevalence, sociodemographic characteristics and spatial distribution of systemic lupus erythematosus in France: a nationwide study using health claims data with insights into hydroxychloroquine prescription patterns.Lupus science & medicine · 2025Article
- The Role of Type I Interferons in Tuberculosis and in Tuberculosis-Risk-Associated Comorbidities.Infectious disease reports · 2025Review
- Review
- Bacterial infection in patients with juvenile systemic lupus erythematosus and fever.Pediatric rheumatology online journal · 2025Article
- Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics.Signal transduction and targeted therapy · 2025Review
- MicroRNA-203 Expression as Potential Biomarker for Lupus Nephritis.International journal of nephrology and renovascular disease · 2025Article
- Mapping the spatial and temporal frequency of systemic lupus erythematosus in Brazil.Revista brasileira de epidemiologia = Brazilian journal of epidemiology · 2025Article
- Lupus and other autoimmune diseases: Epidemiology in the population of African ancestry and diagnostic and management challenges in Africa.The journal of allergy and clinical immunology. Global · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) may be more prevalent among most ethnic groups in the low-and-middle income countries (LMICs), still these countries are under-represented in epidemiological data on SLE. The aim of this study was to review the prevalence and incidence of SLE in LMICs and use meta-analytic techniques. The MEDLINE, CINHAL, Web of Science, Scopus and Global Index Medicus databases were searched for relevant studies published up to July of 2022. Papers selected for full-text review were included in the systematic review if they provided the prevalence or incidence of SLE in LMICs and published in English language. The reference lists of included articles were also searched for additional studies. Two individuals independently performed abstract and full-text review, data extraction, and quality assessment of the papers. The prevalence and incidence of SLE were pooled through random effects model. Pooled estimates were expressed with 95% confidence. Out of 2340 papers, 23 studies were included in the review. The mean age at diagnosis ranged from 25.5 to 45.8 years. Three studies were conducted in Argentina and Brazil, two studies in China and one study in Cuba, Colombia, Democratic Republic Congo, Ecuador, Egypt, India, Kenya, Malaysia, Mexico, Nigeria, Pakistan, Turkey, Ukraine, Venezuela, and Zimbabwe. The SLE prevalence and incidence varied from 3.2 to 159 per 100,000 and 0.3-8.7 per 100,000 persons, respectively. In a random effects meta-analysis (n = 10), the pooled prevalence of SLE was 103 (95% confidence interval [CI] - 17 to 224) per 100,000. Meta-analysis of data from 6 incidence studies revealed an incidence of 5 cases per year (95% CI 2-8) per 100,000. According to WHO regions, the pooled prevalence of American and Western Pacific regions was 300 (95% CI - 200 to 900) and 36 (95% CI 35-37) per 100,000, respectively. The pooled incidence of the American region was 10 (95%, 0-14) per 100,000 inhabitants. Systemic lupus erythematosus is a common disease with considerable variation in prevalence and incidence among the general population in LMICs. Accurate estimates of prevalence and incidence of SLE are required to put in place appropriate programmes to reduce its burden in LMICs. PROSPERO registration number: CRD: 42020197495, https://www.crd.york.ac.uk/prospero/ .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.